目的:观察光动力疗法(PDT)联合bevacizumab治疗中心渗出性脉络膜视网膜病变(CEC)临床疗效与安全性。方法:选取40例40眼患者平均年龄35.5岁,就诊时最佳矫正视力:0.04～0.6,经眼底检查、FFA与OCT检查确诊CEC,对比分析治疗前后的视力、眼底像、FFA及OCT检查结果,统计1次PDT治疗后CNV未完全闭合眼数,bevaci-zumab注射次数,观察治疗的安全性。40眼PDT均治疗1次,1mo时复查FFA,OCT,30眼CNV完全闭合,10眼发现CNV部分或未完全闭合,渗漏扩大,CNV部分或未完成闭合眼给予bevacizumab1.5mg球内注射。第3mo复查时,30眼CNV完全闭合中5眼CNV再次渗漏并给予bev-acizumab1.5mg球内注射,每月再次复查,治疗后随访12mo,6眼bevacizumab注射3次。结果:联合治疗视力提高≥2行者34眼(85%),视力稳定5眼(12.5%),视力下降2行者1眼(2.5%),FFA显示34眼CNV完全闭合,5眼CNV部分闭合,1眼CNV扩大。结论:光动力疗法联合bevacizumab球内注射治疗CEC。1次PDT治疗后,每月复查FFA及OCT,CNV部分未闭合或扩大者改注射bevacizumab,减少了PDT治疗次数,提高CNV闭合率是安全经济有效的。

AIM:To investigate the therapeutic effect of photo-dynamic therapy (PDT) combined with bevacizumab on central exudative chorioretinopthy(CEC). ·METHODS:Clinical data of 40 patients who had undergone PDT combined with bevacizumab because of choroidal neovascularisation caused by CEC,diagnosed by examination of best-corrected visual acuity (BCVA),ocular fundus fluorescein angiography (FFA),and optical coherence tomography (OCT),were retrospectively an-alyzed. The changes of the BCVA,ocular fundus charac-teristics,and the results of FFA and OCT before and after combined therapy were observed and analyzed. The numeration of the times of retreatment and the safety of the combination therapy were analyzed. ·RESULTS:At the end of the follow-up period after combination therapy,the BCVA improved more than 2 lines in 34 eyes,stabled in 5 eyes,lost more than 2 lines in 1 eye. ·CONCLUSION:PDT combined with bevacizumab the-rapy is an effective and safety therapy for most patients with CEC.

R774.1